THE IMPACT OF ENDOGENOUS AND EXOGENOUS SEX HORMONES ON THE COURSE OF PORPHYRIA IN WOMEN: A NARRATIVE REVIEW

Zofia Tarnawska; Karolina Figiel; Maciej  Krzesimir Kuświk; Mateusz Zawisza; Wojciech Sontag; Mateusz Gawin; Mateusz Gadzina; Emilia Koziara; Julia Gawlak; Aleksandra Golec

doi:10.31435/ijitss.3(51).2026.6186

Authors

Zofia Tarnawska Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland https://orcid.org/0009-0004-2265-8089
Karolina Figiel Szpital Powiatowy w Chrzanowie, Chrzanów, Poland https://orcid.org/0009-0002-2227-5198
Maciej Krzesimir Kuświk University Hospital in Poznań, ul. Przybyszewskiego 49, 60-355 Poznań, Poland https://orcid.org/0009-0006-1925-204X
Mateusz Zawisza Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland https://orcid.org/0009-0003-1981-6640
Wojciech Sontag Zagłębiowskie Centrum Onkologii Szpital Specjalistyczny im. Sz. Starkiewicza, Dąbrowa Górnicza, Poland https://orcid.org/0009-0004-6749-0224
Mateusz Gawin Sosnowiecki Szpital Miejski sp. z o.o. w restrukturyzacji, Sosnowiec, Poland https://orcid.org/0009-0006-7409-9586
Mateusz Gadzina Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach, Katowice, Poland https://orcid.org/0009-0001-6153-4896
Emilia Koziara Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA im. Sierżanta Grzegorza Załogi w Katowicach, Katowice, Poland https://orcid.org/0009-0005-4454-6085
Julia Gawlak Szpital Specjalistyczny im. Jędrzeja Śniadeckiego w Nowym Sączu, Nowy Sącz, Poland https://orcid.org/0009-0002-4586-4200
Aleksandra Golec Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland https://orcid.org/0009-0004-9105-350X

DOI:

https://doi.org/10.31435/ijitss.3(51).2026.6186

Keywords:

Acute Hepatic Porphyrias, Sex Hormones, Hormonal Contraception, Pregnancy, Gonadotropin-Releasing Hormone Agonists, Catamenial Porphyria

Abstract

Porphyrias are a group of metabolic diseases caused by an impairment of the heme synthesis pathway, resulting in the accumulation of heme precursors. First symptoms usually occur during puberty and can be triggered by a range of factors such as drugs, alcohol, fasting, infection, and, most importantly for this study, hormonal changes. Women in the reproductive age are known to be the main group presenting with porphyria symptoms (1.5–2.5 times more frequent in women than in men) mainly due to higher concentrations of steroid hormones, particularly progesterone. Hormonal fluctuations associated with the menstrual cycle are the most commonly identified trigger causing an AIP attack in female patients. Pregnancy and exogenous hormone administration may also precipitate attacks in susceptible individuals, although there is considerable interindividual variability, and the underlying mechanisms remain incompletely understood.

This review summarizes existing knowledge on hormonal changes induced by the menstrual cycle, pregnancy, hormonal contraception, and GnRH agonists in women diagnosed with porphyria. It compares it with the conclusions reached by the IPNET panelists in the newly published guidelines, released in May 2026.

The available evidence, derived mainly from retrospective studies, small cohorts, and case reports, indicates that endogenous and exogenous hormones can have a major impact on susceptible women with porphyria. Most data confirmed that the use of oral contraceptives appears to carry the highest risk of precipitating attacks, whereas levonorgestrel-releasing IUDs seem to be better tolerated. GnRH agonist therapy proved highly effective and significantly safer than hormonal contraception in the treatment of recurrent cycle-related porphyria, although it requires add-back therapy, posing a threat itself.

Despite recent advances and the publication of IPNET recommendations, high-quality evidence remains limited. Further prospective studies are required to establish evidence-based recommendations for hormonal management and contraception in women with acute hepatic porphyrias.

References

Aggarwal, A., & Kulshreshtha, B. (2020). Catamenial acute intermittent porphyria managed with GnRH analogues and estrogen and progesterone add-back therapy. Journal of Pediatric and Adolescent Gynecology, 33(4), 432–434. https://doi.org/10.1016/j.jpag.2020.02.009

Andersson, C., Innala, E., & Bäckström, T. (2003). Acute intermittent porphyria in women: Clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. Journal of Internal Medicine, 254(2), 176–183. https://doi.org/10.1046/j.1365-2796.2003.01172.x

Edel, Y., Stein, P. E., Kawtharany, H., Aarsand, A. K., Badminton, M., Balwani, M. C., Bonkovsky, H. L., Cappellini, M. D., Cassiman, D., Deybach, J. C., Gill, L., Harper, P., Hift, R., Kauppinen, R., Ivanova, A., Langendonk, J., Marcacci, M., Minder, A. E., Naik, H., … Sandberg, S. (2026). Guidelines for the management of acute porphyria: Recommendations from the International Porphyria Network. The Lancet. Haematology, 13(5), e338–e350. https://doi.org/10.1016/S2352-3026(26)00044-X

European Medicines Agency. (n.d.). Givlaari (givosiran): Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari

Gilleshammer, L. E., Jensen, H. N., Skeide Kjome, R. L., & Aarsand, A. K. (2024). 04150 Use of hormonal contraceptives and menopausal replacement therapy in women with acute porphyria. BMJ Open Gastroenterology, 11(Suppl. 1). https://doi.org/10.1136/bmjgast-2024-ICPP.3

Gross, U., Honcamp, M., Daume, E., Frank, M., Düsterberg, B., & Doss, M. O. (1995). Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme, 27(8), 379–383. https://doi.org/10.1055/s-2007-979983

Innala, E., Bäckström, T., Bixo, M., & Andersson, C. (2010). Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstetricia et Gynecologica Scandinavica, 89(1), 95–100. https://doi.org/10.3109/00016340903390729

Innala, E., Bäckström, T., Poromaa, I. S., Andersson, C., & Bixo, M. (2012). Women with acute intermittent porphyria have a defect in 5α-steroid production during the menstrual cycle. Acta Obstetricia et Gynecologica Scandinavica, 91(12), 1445–1452. https://doi.org/10.1111/j.1600-0412.2012.01536.x

Jee, S. B., & Sawal, A. (2024). Physiological changes in pregnant women due to hormonal changes. Cureus, 16(3), e55544. https://doi.org/10.7759/cureus.55544

Kanaan, C., Veille, J. C., & Lakin, M. (1989). Pregnancy and acute intermittent porphyria. Obstetrical & Gynecological Survey, 44(4), 244–249. https://doi.org/10.1097/00006254-198904000-00003

Kauppinen, R. (2005). Porphyrias. Lancet (London, England), 365(9455), 241–252. https://doi.org/10.1016/S0140-6736(05)17744-7

Leaf, R., Rebeiz, L., Pocius, K., Tran, B., Bensaber, N., Wang, C., Yeung, P., Wheeden, K., Allan, L., Storjord, E., Moghe, A., Anderson, K., & Dickey, A. (2025). Reproductive health across the lifespan in acute hepatic porphyria. Blood. Advance online publication. https://doi.org/10.1182/blood-2025-1098

Misek, R. K., & Riitano, M. F. (2023). Implanted progestin causing pain and psychiatric disturbances in porphyria attack: A case report. Clinical Practice and Cases in Emergency Medicine, 7(3), 144–147. https://doi.org/10.5811/cpcem.1490

Pischik, E., & Kauppinen, R. (2015). An update of clinical management of acute intermittent porphyria. Application of Clinical Genetics, 8, 201–214. https://doi.org/10.2147/TACG.S48605

Pischik, E., & Kauppinen, R. (2006). Can pregnancy stop cyclical attacks of porphyria? The American Journal of Medicine, 119(1), 88–90. https://doi.org/10.1016/j.amjmed.2005.08.032

Ross, G. (2024). 04095 Hormonal treatments in acute hepatic porphyria. BMJ Open Gastroenterology, 11(Suppl. 1). https://doi.org/10.1136/bmjgast-2024-ICPP.48

Schulenburg-Brand, D., Gardiner, T., Guppy, S., Rees, D. C., Stein, P., Barth, J., Stewart, M. F., & Badminton, M. (2017). An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Reports, 36, 99–107. https://doi.org/10.1007/8904_2017_2

Strome, A., Hawkins, S. D., Huang, Y. Y., & Helfrich, Y. R. (2022). A case report on variegate porphyria after etonogestrel placement. JAAD Case Reports, 22, 104–106. https://doi.org/10.1016/j.jdcr.2022.02.024

Vassiliou, D., & Sardh, E. (2022). Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies. Journal of Internal Medicine, 291(1), 81–94. https://doi.org/10.1111/joim.13376